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AHB and 769 AHC cases with 4,874 hepatitis A cases, used
as controls.
Results: For AHC, the strongest associations were with
urological [Adjusted Odd Ratio (ORadj,17.5; Cinﬁdence
Interval (CI), 1.6—187.1), neurological (ORad, 16.2, CI,
2.7—97.7), and minor surgery (ORad,10.9; CI,3.6—32.6). A
lower but signiﬁcant risk (from 3,7 to 4,7 times higher
respect to no intervention) was found for oral surgery,
Gynaecological, cardiovascular, abdominal interventions
and for biopsy or endoscopy. Only minor (ORad,3.0; CI,
1.3—7.1), oral (ORad, 2.6; CI,1.5—4.6) and dermatological
surgery (ORad, 2.9; CI, 1.1—7.5) were associated with AHB
instead, instead.
Conclusion: Although AHB and AHC incidences are declin-
ing, IP still represent important risk factors. The differences
in risk estimation between AHB and AHC is likely due to
the higher HCV prevalence in the general population; admit-
ting a person-to-person transmission by breaks in universal
precautions, the larger pool of subjects infected with HCV
than HBV makes more likely the exposure to HCV. The
increasing proportion of HBV-immunized young adults and
vaccination of high risk groups, further explain these differ-
ences. The high risk found for minor surgery, might suggest
that healthcare providers underrate the risk connected with
this procedure. Since a lot of people is exposed to IP
and an effective HCV vaccine is not yet available, these
ﬁndings underscore the importance of implementing non-
immunologic preventive measures to control iatrogenic HBV
and HCV transmission.
doi:10.1016/j.ijid.2008.05.1253
67.033
Evaluation of Early Predictors of Successful Therapy in
HCV Infected Patients from Romania
C. Sultana1, L. Manolescu2, S. Ruta2,∗
1 ‘St. S. Nicolau’ Institute of Virology, Bucharest, Romania
2 ‘Carol Davila’ University of medicine and Pharmacy,
Bucharest, Romania
Background: The ability to predict a favorable outcome of
treatment is a major issue in the management of hepatitis C.
Based on results of the viral kinetics studies, which indicated
a two-phase reduction in HCV RNA levels after IFN treatment
initiation, with the ﬁrst one appearing to be predictive of
response, we monitored the utility of the rapid virological
response (RVR), deﬁned as undetectable HCV RNA at week
4.
Methods: Samples from 38 patients (all females, mean
age 48,4± 5 ys) with chronic hepatitis C, but without signs
of cirrhosis, were tested for HCV viral load by quantitative
Rt- PCR (COBAS Amplicor HCV Monitor, Roche Diagnos-
tics) before initiation of treatment with PEG-IFN-alpha-2a
(180mcg/week) in combination with ribavirin (800mg/day)
for 48 weeks, at week 4 and at 6 month after the completion
of therapy. Genotyping was performed using a commercial
Line Probe Assay (Innogenetics).
Results: All patients had high baseline viral load
(>700 0000 IU/ml) and were infected with genotype 1b.
Despite these negative predictors for treatment success,
21 patients (75%) achieved a sustained virologic response
(SVR)- undetectable viral load at 6 month after discontinu-
ation of treatment. At week 4 after treatment initiation, 18
patients (64%) had undetectable viral load HCV. Out of these
rapid responders 17 (95%) achieved a SVR and only relapsed
at 6 month.By contrast, only 4 patients (36.4%) with HCV
RNA≥ 600 IU/ml at week-4 achieved an SVR.
Conclusion: The RVR may be a useful indicator for
the duration and long term outcome of treatment among
patients with chronic HCV infection, even in countries like
Romania, where genotype 1b is the most common. Lack of
RVR can justify discontinuation of therapy, with important
reduction in associated costs and adverse effects, while a
good response at week 4 indicates a low risk of relapses,
even in the presence of a less-sensitive genotype.
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Introduction: Hepatitis C virus (HCV) infection has
reached epidemic proportions. Worldwide, more than one
million new cases of infection are reported annually, and
HCV is believed to be more prevalent than hepatitis B virus
infection and 80% of the affected will be chronically infected
and are at risk of serious chronic sequel including cirrho-
sis and hepatocellolar carcinoma. Genotyping of HCV is
becoming increasingly important for clinical management of
chronic infection and as an epidemiological marker. At least
six major genotypes of HCV, each comprising multiple sub-
types, have been identiﬁed. Substantial regional differences
appear to exist in the distribution of genotypes. Although
HCV genotypes 1, 2, and 3 appear to have a worldwide distri-
bution, their relative prevalence varies from one geographic
area to another. subtypes 1a and 1b in the United States and
Europe, In Japan, subtype 1b, in northern Italy Subtype 2c,
Genotype 4 in North Africa and the Middle East, genotypes
5 and 6 in South Africa and Hong Kong are the most common
genotypes. Genotypes 7, 8, and 9 have been identiﬁed only
in Vietnamese patients, and genotypes 10 and 11 were iden-
tiﬁed in patients from Indonesia. We conducted this study to
detect the most common genotype in major thalassaemics
patients.
Methods and materials: We enrolled 52 patients of
HCV positive in a cross-sectional study. we used ELISA,
Restrictive-Fragment length polymorphism analysis and PCR
methods.
Result: 51.9% were men and 48.1% women. The mean
age (±SD) was 22± 4.48. Genotype 1a was the most com-
mon type (53%) after that 3a (42%) and 1b (5%).average of
viral load in patients with 1a genotype was 363501.1 and
in patients with 3a was 346621.3 that shows no signiﬁcant
difference.
